Pediatrix Medical Group (NYSE:MD - Get Free Report) had its price objective upped by equities researchers at UBS Group from $10.50 to $16.50 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage currently has a "neutral" rating on the stock. UBS Group's target price suggests a potential upside of 6.80% from the company's current price.

Other equities analysts have also issued research reports about the company. StockNews.com raised Pediatrix Medical Group from a "sell" rating to a "hold" rating in a research note on Wednesday, August 7th. Truist Financial lifted their target price on Pediatrix Medical Group from $13.00 to $16.00 and gave the company a "hold" rating in a research report on Monday. Deutsche Bank Aktiengesellschaft lifted their target price on Pediatrix Medical Group from $9.00 to $15.00 and gave the company a "hold" rating in a research report on Monday. Mizuho lifted their target price on Pediatrix Medical Group from $13.00 to $15.00 and gave the company a "neutral" rating in a research report on Monday. Finally, Jefferies Financial Group lifted their target price on Pediatrix Medical Group from $14.00 to $18.00 and gave the company a "buy" rating in a research report on Tuesday. Five research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $16.10.

View Our Latest Report on MD

NYSE MD traded up $0.31 on Tuesday, reaching $15.45. 402,319 shares of the company were exchanged, compared to its average volume of 870,622. The business's fifty day moving average price is $11.70 and its 200 day moving average price is $9.45. The stock has a market capitalization of $1.33 billion, a P/E ratio of -5.05, a price-to-earnings-growth ratio of 2.36 and a beta of 1.55. The company has a current ratio of 1.58, a quick ratio of 1.38 and a debt-to-equity ratio of 0.86. Pediatrix Medical Group has a fifty-two week low of $6.62 and a fifty-two week high of $15.52.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last released its quarterly earnings data on Friday, November 1st. The company reported $0.44 earnings per share for the quarter, topping analysts' consensus estimates of $0.37 by $0.07. The company had revenue of $511.20 million for the quarter, compared to analyst estimates of $498.87 million. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The firm's revenue for the quarter was up .9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.29 earnings per share. Analysts forecast that Pediatrix Medical Group will post 1.19 earnings per share for the current year.

In related news, CFO C Marc Richards sold 32,562 shares of the business's stock in a transaction on Friday, August 9th. The stock was sold at an average price of $10.08, for a total value of $328,224.96. Following the sale, the chief financial officer now owns 192,785 shares in the company, valued at approximately $1,943,272.80. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CFO C Marc Richards sold 32,562 shares of the business's stock in a transaction on Friday, August 9th. The stock was sold at an average price of $10.08, for a total transaction of $328,224.96. Following the completion of the transaction, the chief financial officer now directly owns 192,785 shares of the company's stock, valued at $1,943,272.80. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO James D. Swift sold 11,100 shares of the business's stock in a transaction on Friday, August 30th. The stock was sold at an average price of $10.79, for a total value of $119,769.00. Following the transaction, the chief executive officer now directly owns 170,001 shares of the company's stock, valued at $1,834,310.79. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 68,100 shares of company stock worth $701,889. 1.20% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently bought and sold shares of the stock. nVerses Capital LLC acquired a new position in shares of Pediatrix Medical Group during the 2nd quarter worth about $31,000. Innealta Capital LLC acquired a new position in shares of Pediatrix Medical Group during the 2nd quarter worth about $33,000. Nisa Investment Advisors LLC boosted its position in shares of Pediatrix Medical Group by 47.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company's stock worth $36,000 after acquiring an additional 1,524 shares in the last quarter. CWM LLC boosted its position in shares of Pediatrix Medical Group by 134.0% during the 3rd quarter. CWM LLC now owns 6,427 shares of the company's stock worth $74,000 after acquiring an additional 3,681 shares in the last quarter. Finally, Canada Pension Plan Investment Board acquired a new position in shares of Pediatrix Medical Group during the 2nd quarter worth about $72,000. 97.71% of the stock is owned by institutional investors and hedge funds.

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Before you consider Pediatrix Medical Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pediatrix Medical Group wasn't on the list.

While Pediatrix Medical Group currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.